Jun 8, 2022 4:05pm EDT Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology
Jun 8, 2022 7:00am EDT Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology
Jun 6, 2022 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention
Jun 2, 2022 7:00am EDT Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jun 1, 2022 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
May 31, 2022 7:00am EDT Tonix Pharmaceuticals Announces Two Oral Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) on Prevention of Rejection in Kidney and Heart Allograft Transplantation at the 2022 American Transplant Congress
May 18, 2022 7:00am EDT Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2
May 9, 2022 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
